Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2315]

First-in-human phase 1 study of TAK-931 for solid tumours

Dr Toshio Shimizu - National Cancer Center Hospital (NCCH), Tokyo, Japan

First-in-human phase 1 study of TAK-931 for solid tumours ( Dr Toshio Shimizu - National Cancer Center Hospital (NCCH), Tokyo, Japan )

Matching mutations in tumours to precision medicine improves survival

Prof Apostolia Maria Tsimberidou - MD Anderson Cancer Center, Houston, USA

Matching mutations in tumours to precision medicine improves survival ( Prof Apostolia Maria Tsimberidou - MD Anderson Cancer Center, Houston, USA )

Development of blood tests for early lung cancer

Dr Geoffrey Oxnard - Dana-Farber Cancer Institute, Boston, USA

Development of blood tests for early lung cancer ( Dr Geoffrey Oxnard - Dana-Farber Cancer Institute, Boston, USA )

Editor’s Choice for May 2018

Prof Gordon McVie - Founding Editor, ecancer

Editor’s Choice for May 2018 ( Prof Gordon McVie - Founding Editor, ecancer )

Incorporating biomarkers into clinical trial design

Dr Amar Gajjar - St. Jude Children's Research Hospital, Memphis, USA

Incorporating biomarkers into clinical trial design ( Dr Amar Gajjar - St. Jude Children's Research Hospital, Memphis, USA )

Clinical management of plasma cell leukaemia

Dr Francesca Gay - University of Torino, Torino, Italy

Clinical management of plasma cell leukaemia ( Dr Francesca Gay - University of Torino, Torino, Italy )

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

Biomarkers of pembrolizumab response in head and neck cancer

Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA

Biomarkers of pembrolizumab response in head and neck cancer ( Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA )

Safety indications in mouse models treated with full doses of MEK inhibitors...

Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York...

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099 ( Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA )

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Dr Susan Galbraith - AstraZeneca, Cambridge, UK

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy ( Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA )

Impact of microbiome on head and neck cancers

Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA

Impact of microbiome on head and neck cancers ( Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA )

More from ecancer